Fibrinolytic therapy in subacute bacterial endocarditis: an experimental study

Area of Science:

• Infectious Diseases
• Pharmacology
• Cardiovascular Research

Background:

• Bacterial endocarditis is a serious infection.
• Penicillin is a standard treatment.
• Fibrinolytics are enzymes that break down clots.

Purpose of the Study:

• To investigate the effect of adding a fibrinolytic agent (streptokinase) to penicillin therapy for experimental streptococcal bacterial endocarditis.
• To assess the impact on vegetation size, bacterial sterilization, and embolic events.

Main Methods:

• Experimentally induced streptococcal bacterial endocarditis in rabbits.
• Treatment with intravenous penicillin alone or in combination with intravenous streptokinase.
• Assessment of vegetation size, microbial load, and embolism to lungs and kidneys.

Main Results:

• A 3-day course of streptokinase significantly reduced vegetation size in 9-day-old lesions.
• Combined therapy with streptokinase and penicillin led to more rapid sterilization of vegetations compared to penicillin alone.
• While penicillin reduced embolism, adding streptokinase reversed this protective effect, resulting in embolism rates similar to untreated animals.

Conclusions:

• Streptokinase enhances the efficacy of penicillin in treating bacterial endocarditis by reducing vegetation size and accelerating bacterial clearance.
• The addition of streptokinase to penicillin therapy carries an increased risk of systemic embolism.
• Careful consideration of the risk-benefit profile is necessary when considering fibrinolytic therapy in bacterial endocarditis.